This cost-effectiveness analysis was based on patient-level data for 14,752 patients followed up to 6.7 years, which makes it one of the largest samples for a within-trial economic evaluation of GLP-1 RA use in patients with established type 2 diabetes.[28] Trial outcomes were extrapolated using the UKPDS-OM2,[14] which uses data from a population of UK patients recruited between 1977 and 1991 and followed up until 2007. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.